Evidence map›Paper›PMID 40632300›Full record

ArticleMolecular biology reports2025

Targeting the lncRNA RBM5-AS1/GCN5 axis under fasting conditions reprograms Glycolysis and induces apoptosis in ovarian cancer cells.

Gayathiri Gunasangkaran, Saradhadevi Muthukrishnan, Anjali K Ravi, Vijaya Anand Arumugam, Velayuthaprabhu Shanmugam, Kunnathur Murugesan Sakthivel, Marie Arockianathan Pushpam, Ashokkumar Kaliyaperumal

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Proteomic Identification of ALDOA as a Pathogenic TDP-43 Interaction Partner in ALS.Degenerative neurological and neuromuscular disease · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Gayathiri GunasangkaranDepartment of Biochemistry, Bharathiar University, Coimbatore, Tamilnadu, India.
Saradhadevi MuthukrishnanDepartment of Biochemistry, Bharathiar University, Coimbatore, Tamilnadu, India. saradhadevi@buc.edu.in.
Anjali K RaviDepartment of Biochemistry, Bharathiar University, Coimbatore, Tamilnadu, India.
Vijaya Anand ArumugamDepartment of Human Genetics and Molecular Biology, Bharathiar University, Coimbatore, Tamil Nadu, India.
Velayuthaprabhu ShanmugamDepartment of Biotechnology, Bharathiar University, Coimbatore, Tamilnadu, India.
Kunnathur Murugesan SakthivelDepartment of Biochemistry, PSG College of Arts and Science, Coimbatore, Tamilnadu, India.
Marie Arockianathan PushpamPG & Research, Department of Biochemistry, St. Josephs College of Arts & Science, Cuddalore, Tamilnadu, India.
Ashokkumar KaliyaperumalDepartment of Agriculture and Animal sciences, Gandhigram Rural Institute Deemed University, Gandhigram, 624 302, Tamilnadu, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOvarian cancer is a highly aggressive malignancy influenced by complex molecular interactions, including those involving long non-coding RNAs. RBM5-AS1, a nuclear-retained lncRNA, interacts with GCN5 to acetylate PGC-1α, thereby enhancing the Warburg effect. Although fasting is known to exert antitumor effects by modulating lncRNAs and activating PGC-1α, its impact on the RBM5-AS1/GCN5 axis in ovarian cancer remains underexplored. This study evaluates the therapeutic efficacy of RBM5-AS1 knockdown and GCN5 inhibition under fasting-mimicked conditions in SKOV3 cells. METHODS AND

resultsThe findings of cytotoxicity assays revealed a dose-dependent decrease in cell viability, with the fasting + siRNA + MB-3 combination showing the most potent anticancer effect. LDH assays confirmed enhanced membrane damage in this group. Migration assays demonstrated reduced motility, while DAPI and acridine orange/ethidium bromide staining indicated significant apoptotic features present in fasting + siRNA + MB-3-treated ovarian cancer cells. Colony formation was markedly inhibited under the combination treatment, confirming suppression of clonogenic potential. Flow cytometry analysis revealed > 80% late apoptotic/necrotic cells in the fasting + siRNA + MB-3 group. Gene expression analysis further showed downregulation of Warburg-related genes (PDK1/2/3/4, LDH, GLUT1/3/4) and upregulation of PDH and pro-apoptotic markers (Caspase, Bax), alongside reduced PGC-1α acetylation.

conclusionThese findings indicate that fasting enhances the therapeutic effect of RBM5-AS1 knockdown and GCN5 inhibition, leading to a significant disruption of glycolytic metabolism and promoting apoptosis. This combinatorial approach highlights a promising metabolic and epigenetic strategy for ovarian cancer treatment.

Indexed as

Cell Cycle ProteinsFastingHistone AcetyltransferasesOvarian NeoplasmsRNA-Binding ProteinsRNA, Long NoncodingTumor Suppressor ProteinsApoptosisCell Line, TumorCell MovementCell ProliferationCell SurvivalDNA-Binding ProteinsFemaleGene Expression Regulation, NeoplasticGlycolysisCell Cycle ProteinsDNA-Binding ProteinsHistone Acetyltransferasesp300-CBP-Associated Factorp300-CBP Transcription FactorsPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaRBM5 protein, humanRNA-Binding ProteinsRNA, Long NoncodingTumor Suppressor ProteinsFastingGCN5LncRNA RBM5-AS1Ovarian cancerPGC-1α acetylationWarburg effect

Identifiers

PMID40632300

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.